Klingman Associates Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Klingman Associates reduced its stake in Thermo Fisher Scientific by 70.79% during the most recent quarter end. The investment management company now holds a total of 691 shares of Thermo Fisher Scientific which is valued at $101,473 after selling 1,675 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Apr 18, 2016.Thermo Fisher Scientific makes up approximately 0.04% of Klingman Associates’s portfolio.

Thermo Fisher Scientific closed down -0.5 points or -0.34% at $146.85 with 10,14,583 shares getting traded on Friday. Post opening the session at $147.47, the shares hit an intraday low of $145.6401 and an intraday high of $147.94 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Osborn Rohs Williams Donohoe Ltd reduced its stake in TMO by selling 50 shares or 0.87% in the most recent quarter. The Hedge Fund company now holds 5,705 shares of TMO which is valued at $829,165. Thermo Fisher Scientific makes up approx 0.16% of Osborn Rohs Williams Donohoe Ltd’s portfolio.Simplex Trading reduced its stake in TMO by selling 7,669 shares or 47.25% in the most recent quarter. The Hedge Fund company now holds 8,562 shares of TMO which is valued at $1,244,401. Thermo Fisher Scientific makes up approx 0.19% of Simplex Trading’s portfolio. Acadian Asset Management sold out all of its stake in TMO during the most recent quarter. The investment firm sold 64 shares of TMO which is valued $9,302. Bkd Wealth Advisors sold out all of its stake in TMO during the most recent quarter. The investment firm sold 1,444 shares of TMO which is valued $209,871.

On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.